Management of patient with acute coronary syndrome without ST elevation: focusing on antithrombotic therapy

Ya.M. Lutai, A.N. Parkhomenko, O.I. Irkin, S.P. Kushnir


The article discusses the clinical case of a patient with acute coronary syndrome without ST elevation complicated by acute heart failure symptoms, and multivessel coronary artery disease. The approaches to the treatment of such patients according to modern recommendations and protocols are considered.


acute coronary syndrome; antithrombotic the­rapy


Angiolillo D.J., Jakubowski J.A., Ferreiro J.L., Tello-Montoliu A., Rollini F., Franchi F., Ueno M., Darlington A., Desai B., Moser B.A., Sugidachi A., Guzman L.A., Bass T.A. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease // J. Am. Coll. Cardiol. — 2014. — № 64. — Р. 1005-1014. — doi: 10.1016/j.jacc.2014.06.1170.

Becker R.C., Bassand J.P., Budaj A., Wojdyla D.M., James S.K., Cornel J.H., French J., Held C., Horrow J., Husted S., Lopez-Sendon J., Lassila R., Mahaffey K.W., Storey R.F., Harrington R.A., Wallentin L. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial // Eur. Heart J. — 2011. — № 32. — Р. 2933-44.

Chen I.C., Lee C.H., Fang C.C., Chao T.H., Cheng C.L., Chen Y. et al. Efficacy and safety of ticagrelor versus clopidogrel in acute coronary syndrome in Taiwan: a multicenter retrospective pilot study // J. Chin. Med. Assoc. — 2016. — № 79. — Р. 521e30.

Gosling R., Yazdani M., Parviz Y., Hall I.R., Grech E.D., Gunn J.P. Comparison of P2Y12 inhibitors for mortality and stent thrombosis in patients with acute coronary syndromes: Single center study of 10 793 consecutive ‘real-world’ patients // Platelets. — 2017. — Р. 1-7.

Hansson E.C., Jideus L., Aberg B. еt al. Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study // Eur. Heart J. — 2016. — № 37. — Р. 189-197.

Held C., Asenblad N., Bassand J.P. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndrome sundergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial // J. Am. Coll. Cardiol. — 2011. — № 57(6). — Р. 672-684.

Husted S. et al. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized Platelet Inhibition and Patient Outcomes (PLATO) trial // Circ. Cardiovasc. Qual. Outcomes. — 2012. — № 5. — Р. 680-688.

James S.K. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ische­mic attack // Circulation. — 2012. — № 125. — Р. 2914-2921.

James S. et al. Ticagrelor versus clopidogrel in acute coro­nary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial // Circulation. — 2010. — № 122. — Р. 1056-1067.

James S. et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the Platelet Inhibition and Patient Outcomes (PLATO) trial // Eur. Heart J. — 2010. — № 31. — Р. 3006-3016.

Johnston S.C., Amarenco P., Albers G.W., Denison H., Easton J.D., Evans S.R., Held P., Jonasson J., Minematsu K., Molina C.A., Wang Y., Wong K.S.; SOCRATES Steering Committee and Investigators. Ticagrelor versus aspirin in acute stroke or transient ischemic attack // N. Engl. J. Med. — 2016. — № 375. — Р. 35-43.

Levine G.N., Bates E.R., Bittl J.A., Brindis R.G., Fihn S.D., Fleisher L.A., Granger C.B., Lange R.A., Mack M.J., Mauri L., Mehran R., Mukherjee D., Newby L.K., O’Gara P.T., Sabatine M.S., Smith P.K., Smith S.C. Jr. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American college of Cardiology/American heart association task force on clinical practice guidelines // J. Am. Coll. Cardiol. — 2016. — № 68. — Р. 1082-1115.

Lindholm D., Varenhorst C., Cannon C.P., Harrington R.A., Himmelmann A., Maya J., Husted S., Steg P.G., Cornel J.H., Storey R.F., Stevens S.R., Wallentin L., James S.K. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial // Eur. Heart J. — 2014. — № 35. — Р. 2083-2093.

Gurbel P.A., Bliden K.P., Butler K. et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study // Circulation. — 2009. — № 120(2009). — Р. 2577-2585.

Roffi M., Patrono C., Collet J.-P. et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC) // Eur. Heart J. — 2016. — № 37(3). — Р. 267-315.

Sahlen A., Varenhorst C., Lagerqvist B., Renlund H., Omerovic E., Erlinge D., Wallentin L., James S.K., Jernberg T. Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry // Eur. Heart J. — 2016. — № 37(44). — Р. 3335-3342.

Sousa-Uva M., Storey R., Huber K. Et al. ESC Wor­king Groupon Cardiovascular Surgery and ESC Working Groupon Thrombosis. Expert positi on paperon the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery // Eur. Heart J. — 2014. — № 35(23). — Р. 1510-1514.

Stent Thrombosis with Ticagrelor versus Clopidogrel after Percutaneous Coronary Intervention and Ticagrelor or Clopidogrel in Patients with Acute Coronary Syndromes in a Real World Setting / Christian O. Fallesen, Per Thayssen, Knud Erik Pe­dersen, Anders Junker, Knud N. Hansen, Henrik S. Hansen, Karsten T. Veien, Lisette Okkels Jensen // JACC. — 2014. — Vol. 64(11, Suppl. B).

Subherwal S., Bach R.G., Chen A.Y., Gage B.F., Rao S.V., Newby L.K., Wang T.Y., Gibler W.B., Ohman E.M., Roe M.T., Pollack C.V. Jr, Peterson E.D., Alexander K.P. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) bleeding score // Circulation. — 2009. — № 119. — Р. 1873-1882.

Szummer K., Oldgren J., Lindhagen L., Carrero J.J., ­Evans M., Spaak J. et al. Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction // JAMA. — 2015. — № 313. — Р. 707-16.

Varenhorst C., Alstrоm U., Scirica B.M., Hogue C.W., Asenblad N., Storey R.F., Steg P.G., Horrow J., Mahaffey K.W., Becker R.C., James S., Cannon C.P., Brandrup-Wognsen G., Wallentin L., Held C. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery // J. Am. Coll. Cardiol. — 2012. — № 60. — Р. 1623-1630.

Wallentin L., Becker R.C., Budaj A. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes // N. Engl. J. Med. — 2009. — № 361. — Р. 1045-57.

Yusuf S., Mehta S.R., Chrolavicius S. et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes // N. Engl. J. Med. — 2006. — № 354. — Р. 1464-76.

Уніфікований клінічний протокол екстреної, первинної, вторинної (спеціалізованої), третинної (високоспеціалізованої) медичної допомоги та медичної реабілітації «Гострий коронарний синдром без елевації сегмента ST».



  • There are currently no refbacks.

Copyright (c) 2018 EMERGENCY MEDICINE

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2018


   Seo анализ сайта